PipelineReview.com17h
AbbVie Announces Positive Topline Results from Phase 3 TEMPO-1 Trial Evaluating Tavapadon as a Monotherapy for Parkinson’s Disease
NORTH CHICAGO, IL, USA I6, 2024 I AbbVie (NYSE: ABBV) today announced positive topline results from its pivotal Phase 3 TEMPO-1 trial for ...
PipelineReview.com17h
Repair Biotechnologies and Genevant Sciences to Collaborate to Develop mRNA-LNP Therapy with First-in-Class Potential to Turn Back Atherosclerosis
SYRACUSE, NY, USA; VANCOUVER, Canada; and BASEL, Switzerland I6, 2024 I Repair Biotechnologies, a biotechnology company developing first-in-class ...
PipelineReview.com17h
ReCode Therapeutics Doses First Patient in Phase 1b Clinical Study of RCT2100 for the Treatment of Cystic Fibrosis
Phase 1b study will evaluate the safety and tolerability of multiple ascending doses of RCT2100 in people with cystic fibrosis – ...
PipelineReview.com15h
Sage Therapeutics Announces Discontinuation of the Collaboration with Biogen on the SAGE-324 Program
Sage and Biogen will continue to partner on ZURZUVAE®, the first and only FDA-approved oral treatment for women with postpartum depression CAMBRIDGE, MA, USA I September 26, 2024 I Sage Therapeutics, ...
PipelineReview.com1d
Pfizer Voluntarily Withdraws All Lots of Sickle Cell Disease Treatment OXBRYTA® (voxelotor) From Worldwide Markets
NEW YORK, NY, USA I September 25, 2024 I Pfizer Inc. (NYSE: PFE) announced today that it is voluntarily withdrawing all lots of OXBRYTA ® (voxelotor) for the treatment of sickle cell disease (SCD) at ...
PipelineReview.com1d
Innovent Announces NMPA Acceptance of NDA for Picankibart (Anti-IL-23p19 Antibody) for Treating Moderate to Severe Plaque Psoriasis
SAN FRANCISCO, CA, USA and SUZHOU, China I September 26, 2024 I Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical ...
PipelineReview.com1d
Tagrisso approved in the US for patients with unresectable, Stage III EGFR-mutated lung cancer
Based on LAURA Phase III trial results which showed Tagrisso extended median progression-free survival by more than three years ...
PipelineReview.com1d
Positive Phase III Results for Genentech’s Gazyva Show Superiority to Standard Therapy Alone in People With Lupus Nephritis
The REGENCY study met its primary endpoint, demonstrating statistically significant and clinically meaningful treatment benefits in people with active lupus ...
PipelineReview.com1d
The World First Liquid Formulation of Recombinant Botulinum Toxin Type A Has Obtained IND Approval by the FDA
CHONGQING, China I September 25, 2024 I MingMed Biotechnology, an innovative company focused on the in-house discovery and development of novel drugs, recently announced that its partially owned ...
PipelineReview.com1d
PolTREG starts preclinical CAR-Treg development for neuroinflammatory autoimmune diseases
GDANSK, Poland I6, 2024 I PolTREG S.A. (Warsaw Stock Exchange: PTG), a clinical-stage biotechnology company developing cellular therapies for a ...
PipelineReview.com1d
Kyowa Kirin Announces Top-line Data from Rocatinlimab Phase 3 ROCKET HORIZON Trial for Adults with Moderate to Severe Atopic Dermatitis
TOKYO, Japan I5, 2024 I Kyowa Kirin Co., Ltd. (Kyowa Kirin) (TSE:4151) (President and CEO: Masashi Miyamoto) announced top-line results of the ...
PipelineReview.com1d
KSQ Therapeutics Announces FDA Clearance of IND Application for KSQ-004EX, a CRISPR/Cas9 Engineered Tumor-Infiltrating Lymphocyte (eTIL®) Therapy
Phase 1/2 clinical study will evaluate the safety and preliminary efficacy of KSQ-004EX in advanced solid tumors ...